Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Noninvasive lung impedance monitoring improves outcomes in HFpEF patients

29

Mar 2026

Noninvasive lung impedance monitoring improves outcomes in HFpEF patients

Treatment management guided by the use of a noninvasive device to monitor fluid accumulation in the lungs substantially reduced hospitalizations and deaths among patients with heart failure with preserved ejection fraction (HFpEF), according to research presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

Trial shows mavacamten benefits adolescents with obstructive heart condition

29

Mar 2026

Trial shows mavacamten benefits adolescents with obstructive heart condition

Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant improvement in left ventricular outflow tract (LVOT) gradient, a measure of blood flow obstruction in the heart, compared with those who received a placebo, according to a small study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

Left-ventricular unloading during angioplasty fails to improve patient outcomes

29

Mar 2026

Left-ventricular unloading during angioplasty fails to improve patient outcomes

The first randomized trial to compare standard percutaneous coronary intervention (PCI), also known as coronary angioplasty, with PCI accompanied by the use of a temporary, miniaturized pump to support the heart in patients with both severe coronary heart disease and moderate to severe heart failure found no significant difference between the two approaches.

Novel vFFR method performs similar to invasive coronary assessment

29

Mar 2026

Novel vFFR method performs similar to invasive coronary assessment

A novel, minimally invasive method of determining whether fatty deposits in a coronary artery are restricting blood flow to a patient's heart performed similarly to the standard, more-invasive procedure in a large multi-country European randomized trial presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

AI-based tool matches standard method for coronary blood flow assessment

29

Mar 2026

AI-based tool matches standard method for coronary blood flow assessment

A novel, minimally invasive computer software-based method that uses artificial intelligence to determine whether plaques in a coronary artery are restricting blood flow to the patient's heart performed similarly to the standard, more invasive wire-based procedure, according to a large international randomized trial presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

Higher sugar intake raises gallstone risk in adults, study finds

29

Mar 2026

Higher sugar intake raises gallstone risk in adults, study finds

A cross-sectional NHANES study of 8,975 U.S. adults found that higher total dietary sugar intake was associated with higher odds of gallstones, with each 100 g/day increase linked to a 41% rise after full adjustment. The findings suggest sugar intake may be a modifiable gallstone risk factor, but the study relied on self-reported gallstones and cannot establish causation.

APOE4 alters brain immunity and cognition differently in females and males

29

Mar 2026

APOE4 alters brain immunity and cognition differently in females and males

APOE4 drove sex-specific changes in meningeal immunity, lymphatic drainage, brain lipids, neuroinflammation, and cognition in mouse models, with females showing greater inflammatory and cognitive vulnerability. Suppressing innate immunity improved some cognitive outcomes in female E4/E4 mice but worsened them in male E4/E4 mice, underscoring the need for sex-tailored approaches.

Intensive LDL cholesterol-lowering shows major benefits for heart disease patients

28

Mar 2026

Intensive LDL cholesterol-lowering shows major benefits for heart disease patients

Using cholesterol-lowering medications more intensively to achieve a more aggressive target for low-density lipoprotein cholesterol (LDL-C) reduced the rate of major cardiovascular events by one-third among patients with atherosclerotic cardiovascular disease (ASCVD), according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

Evolocumab reduces cardiac events in high-risk diabetic patients

28

Mar 2026

Evolocumab reduces cardiac events in high-risk diabetic patients

The cholesterol-lowering therapy evolocumab reduced the risk of major adverse cardiac events by nearly one-third among patients who had no known significant atherosclerosis and had diabetes, according to a study presented at the American College of Cardiology's Annual Scientific Session.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.